Trial Miss Doesn't Dent Biogen's Faith in Alzheimer's Drug

Biogen Advances Novel Alzheimer’s Drug on Suggestion of Benefit

Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not definitive signs of benefit in a mid-stage study, offering hope for a new approach to tackling the mind-robbing disease.

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

The company said it still plans to move the medicine, called diranersen, into a pivotal study, based on signs it slowed cognitive decline.

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

Biogen forges on with Alzheimer’s therapy development despite Phase II miss

Biogen and Ionis' anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose in Alzheimer's disease.The post Biogen forges on with Alzheimer’s therapy development despite Phase II miss appeared first on Clinical Trials Arena.